Catalyst Dossier · compiled by CeliA 🧫

ACADIA Pharmaceuticals Inc. (ACAD)

Pharmaceutical Preparations · market cap $3.7B · as of 2026-06-28

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

ACADIA Pharmaceuticals (ACAD) is a ~$4.3B market-cap specialty biopharma with one commercial product, pimavanserin tartrate (approved for Parkinson's Disease Psychosis), generating $1.07B in 2025 revenue and now profitable at a $391M net income level. The company is pursuing label expansions of pimavanserin into Dementia-related Psychosis and Alzheimer's Agitation/Aggression, while a diversified pipeline includes trofinetide (Rett Syndrome), ACP-204 (Lewy Body Dementia Psychosis), and several early-stage assets.

The catalyst path

2026-08-05Earningsimp 5/10

Pipeline

Asset	Phase	Indication
ACP-044 Dose A	Phase 2	Acute Postoperative Pain
Pimavanserin 34 mg	Phase 3	Dementia-related Psychosis
ACP-103	Phase 2	Hallucinations
pimavanserin tartrate	Phase 3	Parkinson's Disease Psychosis
Trofinetide	Phase 3	Rett Syndrome
Pimavanserin tartrate (ACP-103)	Phase 3	Parkinson's Disease Psychosis
ACP-104	Phase 2	Schizophrenia
Carbetocin	Phase 3	Hyperphagia in Prader-Willi Syndrome
ACP-211	Phase 2	Major Depressive Disorder (MDD)
Pimavanserin	Phase 3	Agitation and Aggression in Alzheimer's Disease
ACP-204	Phase 3	Lewy Body Dementia Psychosis

Price & technical context

3-month

+13.2%

6-month

-7.6%

12-month

+18.6%

52-wk range

$20.06–$28.06

vs 50-day MA

+14.3%

vs 200-day MA

+8.3%

Realized vol

48.6%

Max drawdown

-30.5%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ACAD (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.